EURAS Progress Meeting in Lisbon

From 17–19 June 2026, the EURAS consortium gathered in Lisbon, Portugal, for its annual consortium meeting. Hosted by project partner IST-ID (Instituto Superior Técnico, Universidade de Lisboa), the meeting brought together researchers, clinicians, patient representatives, and R&I experts from across Europe to review progress, strengthen collaborations, and define the next steps of the project.

Over the course of three days, consortium members presented updates from the different work packages and reviewed the project's progress towards developing new treatment strategies for neurodevelopmental RASopathies. Discussions covered key aspects of the research pipeline, including the development of patient-derived disease models, the identification of disease mechanisms and biomarkers, patient registries and real-world evidence, innovative drug screening approaches, and novel strategies for delivering therapies to the brain. Particular emphasis was placed on integrating results across the work packages, strengthening collaborations between partners, and aligning future research activities to maximise the project's scientific and clinical impact.

Alongside the scientific programme, partners exchanged on cross-cutting topics such as exploitation of project results, communication and dissemination activities. These discussions help ensure that scientific advances are effectively translated into meaningful outcomes for patients, healthcare professionals, and the wider rare disease community.

Bringing together experts from diverse disciplines remains one of the key strengths of EURAS, enabling close collaboration across institutions and fostering the exchange of knowledge between researchers, clinicians, patient representatives, and innovation experts. This collaborative approach continues to drive the project towards its shared goal of improving the lives of people living with neurodevelopmental RASopathies.